Avvinity is developing novel immunotherapeutics targeted to cancer, harnessing a natural immune adaptation by humans and other primates.
Location: United Kingdom, England, Landbeach
Employees: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| 24.09.2020 | NCL Techno... | ncltv.co.u... |
Mentions in press and media 2
| Date | Title | Description |
| 23.09.2020 | LifeArc and Future Fund provide £3.0m in funding to Avvinity Therapeutics | LifeArc and UK government’s Future Fund provide £3.0m in funding to Avvinity Therapeutics to drive development of new cancer therapies 23rd September 2020 – LifeArc, an independent medical research charity, announces a £3.0m co-investment ... |
| 02.03.2016 | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited 02-03-2016 Horizon Discovery Group plc, the leading international gene editing company, announces today that it has formed an immuno-oncology joint venture, Avvi... |